I'm excited about this announcement and looking forward to updates next Wednesday.
@MAX25 Incredible ignorance, don't invest in sectors you know nothing about. Swab turnaround time 24-72 hours, App turnaround time, instant. You don't swab for Asthma/AECOPD/Croup, the list goes on.
Resappdx has been rolled out on IOS only, I'm pleased they haven't done an enormous advertising push yet and look forward to that happening once the tech is being used by both Android and IOS with some time for "real world use" bug fixing etc. Good things take time, It's like people think CSL announced every bag of product sold at the start, a lot of commentators on here sound so entitled as though they want daily coddling from management, I say let management do their job and find your coddling somewhere else.
@hoofa You've come out of nowhere criticising lack of commercialisation at every turn but only since commercialisation began. Where were you with these criticisms before the products launched? Nothing you say makes sense in the context of where RAP is today, your comments might have been appropriate a year ago. Another ignorant sounding ramper, numbers will come in time, good things take time.
Dollars are coming in, I'm sure we will hear numbers and projections when the time is right, I don't understand the people who seem to waste their lives whinging on HC instead of spending it trying to understand how businesses work or to better understand the sector itself.
To all the Fanboys/girls of Respiri, good job, your company is moving in the right direction. Please stop trying to ruin the days of hundreds of RAP Investors here because of a personal beef you have with one user.
To the faithful RAP investors; I know it's been hard at times but if you can take the emotion out and look at the facts you will probably feel better.
1. Resappdx is now functional and has the potential to be a tool used millions of times a week worldwide, I've said it before and I'll say it again, this is the direction healthcare is heading, someone will deliver the service and it seems Resapp is years ahead of its nearest competitor.
2. Sleepcheck is in its infancy, potential is there for it to be more than a screening tool one day and global rollout is on the way.
3. Relationship with Illara is an enormous positive, I look forward to similar relationships with providers internationally especially in geographical areas where remote assessment using tools like Resapp will become the rule not the exception.
4. Continuous monitoring of people with Chronic Respiratory conditions COPD/Asthma has enormous potential, Seeing people suffering from these conditions briefly in clinic paints a very limiting picture and having continuous data will change lives.
5. RB is an enormous entity, If a DTC product or one used in conjunction with a pharmacists becomes a reality (Over 11000 Pharmacies in the UK) This could be worth a lot of money. Again as before, this is the way healthcare is heading, someone will get there, hopefully Resapp who are leading the way.
Personally I couldn't be more excited to be an investor in a company with this much scalability with products that could easily be the rule not the exception. If uptake isn't as fast as you personally would like, instead of whinging on here go and research the healthcare giants that came before and become familiar with the challenges they faced rolling out the products they are known for today. Thanks to all the people on here who post well researched material and share the correspondence they have with the company, I find it very helpful and to all the devils advocates who actually post thoughtful well researched content I appreciate you as well. DYOR
